Antagonism of EGFR and Notch limits resistance to EGFR inhibitors and radiation by decreasing tumor-initiating cell frequency

Science Translational Medicine

Volumn 9, Issue 380, 2017, Pages

  Hu, Shi ^a   Fu, Wenyan ^b,c   Li, Tian ^a   Yuan, Qingning ^a   Wang, Feifei ^a   Lv, Gaojian ^a   Lv, Yuanyuan ^a   Fan, Xiaoyan ^a   Shen, Yafeng ^a   Lin, Fangxing ^a   Tang, Ying ^a   Ye, Xuting ^a   Yang, Yongji ^a   Lei, Changhai ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CETUXIMAB; CT16 ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; NOTCH2 RECEPTOR; NOTCH3 RECEPTOR; TAREXTUMAB; UNCLASSIFIED DRUG; ALDEHYDE DEHYDROGENASE; ANTINEOPLASTIC AGENT; NOTCH RECEPTOR; PROTEIN KINASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; CANCER STEM CELL; CELL PROLIFERATION; CELL SUBPOPULATION; CONTROLLED STUDY; DNA REPAIR; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER CELL LINE; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; RADIOSENSITIVITY; SIGNAL TRANSDUCTION; TUMOR RECURRENCE; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOGENESIS; CELL COUNT; DRUG EFFECTS; DRUG RESISTANCE; LUNG TUMOR; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; RADIATION TOLERANCE; SCID MOUSE; TUMOR CELL LINE;

ALDEHYDE DEHYDROGENASE; ANIMALS; ANTIBODIES; ANTINEOPLASTIC AGENTS; CARCINOGENESIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL COUNT; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; LUNG NEOPLASMS; MICE, SCID; MOLECULAR TARGETED THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASTIC STEM CELLS; PROTEIN KINASE INHIBITORS; RADIATION TOLERANCE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION;

EID: 85014902478     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aag0339     Document Type: Article

References (54)

1. J. E. Visvader, G. J. Lindeman, Cancer stem cells: Current status and evolving complexities. Cell Stem Cell 10, 717-728 (2012).
2. M. D. Brooks, M. L. Burness, M. S. Wicha, Therapeutic implications of cellular heterogeneity and plasticity in breast cancer. Cell Stem Cell 17, 260-271 (2015).
3. C. J. Creighton, X. Li, M. Landis, J. M. Dixon, V. M. Neumeister, A. Sjolund, D. L. Rimm, H. Wong, A. Rodriguez, J. I. Herschkowitz, C. Fan, X. Zhang, X. He, A. Pavlick, M. C. Gutierrez, L. Renshaw, A. A. Larionov, D. Faratian, S. G. Hilsenbeck, C. M. Perou, M. T. Lewis, J. M. Rosen, J. C. Chang, Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc. Natl. Acad. Sci. U.S.A. 106, 13820-13825 (2009).
4. + cells display stem-like features and are spared by cisplatin treatment. Proc. Natl. Acad. Sci. U.S.A. 106, 16281-16286 (2009).
5. M. Maugeri-Saccà, M. Bartucci, R. De Maria, DNA damage repair pathways in cancer stem cells. Mol. Cancer Ther. 11, 1627-1636 (2012).
6. X. Li, M. T. Lewis, J. Huang, C. Gutierrez, C. K. Osborne, M.-F. Wu, S. G. Hilsenbeck, A. Pavlick, X. Zhang, G. C. Chamness, H. Wong, J. Rosen, J. C. Chang, Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J. Natl. Cancer Inst. 100, 672-679 (2008).
7. M. K. Nyati, M. A. Morgan, F. Y. Feng, T. S. Lawrence, Integration of EGFR inhibitors with radiochemotherapy. Nat. Rev. Cancer 6, 876-885 (2006).
8. L. Li, H. Wang, E. S. Yang, C. L. Arteaga, F. Xia, Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells. Cancer Res. 68, 9141-9146 (2008).
9. B. Mukherjee, H. Choy, C. Nirodi, S. Burma, in Seminars in Radiation Oncology (Elsevier, 2010), Vol. 20, pp. 250-257.
10. J. A. Bonner, P. M. Harari, J. Giralt, N. Azarnia, D. M. Shin, R. B. Cohen, C. U. Jones, R. Sur, D. Raben, J. Jassem, R. Ove, M. S. Kies, J. Baselga, H. Youssoufian, N. Amellal, E. K. Rowinsky, K. K. Ang, Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354, 567-578 (2006).
11. K. K. Ang, Q. Zhang, D. I. Rosenthal, P. F. Nguyen-Tan, E. J. Sherman, R. S. Weber, J. M. Galvin, J. A. Bonner, J. Harris, A. K. El-Naggar, M. L. Gillison, R. C. Jordan, A. A. Konski, W. L. Thorstad, A. Trotti, J. J. Beitler, A. S. Garden, W. J. Spanos, S. S. Yom, R. S. Axelrod, Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J. Clin. Oncol. 32, 2940-2950 (2014).
12. C. Montagut, A. Dalmases, B. Bellosillo, M. Crespo, S. Pairet, M. Iglesias, M. Salido, M. Gallen, S. Marsters, S. P. Tsai, A. Minoche, S. Seshagiri, S. Serrano, H. Himmelbauer, J. Bellmunt, A. Rovira, J. Settleman, F. Bosch, J. Albanell, Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat. Med. 18, 221-223 (2012).
13. W. Pao, V. A. Miller, K. A. Politi, G. J. Riely, R. Somwar, M. F. Zakowski, M. G. Kris, H. Varmus, Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLOS Med. 2, e73 (2005).
14. K. Shien, S. Toyooka, H. Yamamoto, J. Soh, M. Jida, K. L. Thu, S. Hashida, Y. Maki, E. Ichihara, H. Asano, K. Tsukuda, N. Takigawa, K. Kiura, A. F. Gazdar, W. L. Lam, S. Miyoshi, Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells. Cancer Res. 73, 3051-3061 (2013).
15. bright cellular states in EGFR-mutant non-small cell lung cancer: A novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin. Cell Cycle 12, 3390-3404 (2013).
16. R. R. Arasada, J. M. Amann, M. A. Rahman, S. S. Huppert, D. P. Carbone, EGFR blockade enriches for lung cancer stem-like cells through Notch3-dependent signaling. Cancer Res. 74, 5572-5584 (2014).
17. K. Kelly, K. Chansky, L. E. Gaspar, K. S. Albain, J. Jett, Y. C. Ung, D. H. M. Lau, J. J. Crowley, D. R. Gandara, Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J. Clin. Oncol. 26, 2450-2456 (2008).
18. G. D. Goss, C. O'Callaghan, I. Lorimer, M.-S. Tsao, G. A. Masters, J. Jett, M. J. Edelman, R. Lilenbaum, H. Choy, F. Khuri, K. Pisters, D. Gandara, K. Kernstine, C. Butts, J. Noble, T. A. Hensing, K. Rowland, J. Schiller, K. Ding, F. A. Shepherd, Gefitinib versus placebo in completely resected non-small-cell lung cancer: Results of the NCIC CTG BR19 study. J. Clin. Oncol. 31, 3320-3326 (2013).
19. I. Espinoza, L Miele, Notch inhibitors for cancer treatment. Pharmacol. Ther. 139, 95-110 (2013).
20. J.-W. Gu, P. Rizzo, A. Pannuti, T. Golde, B. Osborne, L. Miele, Notch signals in the endothelium and cancer "stem-like" cells: Opportunities for cancer therapy. Vasc. Cell 4, 7 (2012).
21. J. Robbins, B. J. Blondel, D. Gallahan, R. Callahan, Mouse mammary tumor gene int-3: A member of the notch gene family transforms mammary epithelial cells. J. Virol. 66, 2594-2599 (1992).
22. H. Uyttendaele, G. Marazzi, G. Wu, Q. Yan, D. Sassoon, J. Kitajewski, Notch4/int-3, a mammary proto-oncogene, is an endothelial cell-specific mammalian Notch gene. Development 122, 2251-2259 (1996).
23. P. Zagouras, S. Stifani, C. M. Blaumueller, M. L. Carcangiu, S. Artavanis-Tsakonas, Alterations in Notch signaling in neoplastic lesions of the human cervix. Proc. Natl. Acad. Sci. U.S.A. 92, 6414-6418 (1995).
24. T. P. Dang, A. F. Gazdar, A. K. Virmani, T. Sepetavec, K. R. Hande, J. D. Minna, J. R. Roberts, D. P. Carbone, Chromosome 19 translocation, overexpression of Notch3, and human lung cancer. J. Natl. Cancer Inst. 92, 1355-1357 (2000).
25. J. Konishi, K. S. Kawaguchi, H. Vo, N. Haruki, A. Gonzalez, D. P. Carbone, T. P. Dang, γ-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers. Cancer Res. 67, 8051-8057 (2007).
26. J. P. Kumar, K. Moses, EGF receptor and Notch signaling act upstream of Eyeless/Pax6 to control eye specification. Cell 104, 687-697 (2001).
27. J. V. Price, E. D. Savenye, D. Lum, A. Breitkreutz, Dominant enhancers of Egfr in Drosophila melanogaster: Genetic links between the Notch and Egfr signaling pathways. Genetics 147, 1139-1153 (1997).
28. A. T. Baker, A. Zlobin, C. Osipo, Notch-EGFR/HER2 bidirectional crosstalk in breast cancer. Front. Oncol. 4, 360 (2014).
29. S. Schmitz, G. Bindea, R. I. Albu, B. Mlecnik, J.-P. Machiels, Cetuximab promotes epithelial to mesenchymal transition and cancer associated fibroblasts in patients with head and neck cancer. Oncotarget 6, 34288-34299 (2015).
30. J. P. Sullivan, M. Spinola, M. Dodge, M. G. Raso, C. Behrens, B. Gao, K. Schuster, C. Shao, J. E. Larsen, L. A. Sullivan, S. Honorio, Y. Xie, P. P. Scaglioni, J. M. Di Maio, A. F. Gazdar, J. W. Shay, I. I. Wistuba, J. D. Minna, Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res. 70, 9937-9948 (2010).
31. S. Ma, K. W. Chan, T. K.-W. Lee, K. H. Tang, J. Y.-H. Wo, B.-J. Zheng, X.-Y. Guan, Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. Mol. Cancer Res. 6, 1146-1153 (2008).
32. R. L. Yauch, T. Januario, D. A. Eberhard, G. Cavet, W. Zhu, L. Fu, T. Q. Pham, R. Soriano, J. Stinson, S. Seshagiri, Z. Modrusan, C.-Y. Lin, V. O'Neill, L. C. Amler, Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin. Cancer Res. 11 (24 Pt. 1), 8686-8698 (2005).
33. J. P. Medema, Cancer stem cells: The challenges ahead. Nat. Cell Biol. 15, 338-344 (2013).
34. W.-C. Yen, M. M. Fischer, F. Axelrod, C. Bond, J. Cain, B. Cancilla, W. R. Henner, R. Meisner, A. Sato, J. Shah, T. Tang, B. Wallace, M. Wang, C. Zhang, A. M. Kapoun, J. Lewicki, A. Gurney, T. Hoey, Targeting Notch signaling with a Notch2/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency. Clin. Cancer Res. 21, 2084-2095 (2015).
35. J. B. B. Ridgway, L. G. Presta, P. Carter, 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng. 9, 617-621 (1996).
36. S. Atwell, J. B. B. Ridgway, J. A. Wells, P. Carter, Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. J. Mol. Biol. 270, 26-35 (1997).
37. W. Schaefer, J. T. Regula, M. Bähner, J. Schanzer, R. Croasdale, H. Dürr, C. Gassner, G. Georges, H. Kettenberger, S. Imhof-Jung, M. Schwaiger, K. G. Stubenrauch, C. Sustmann, M. Thomas, W. Scheuer, C. Klein, Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc. Natl. Acad. Sci. U.S.A. 108, 11187-11192 (2011).
38. S. Hu, W. Fu, W. Xu, Y. Yang, M. Cruz, S. D. Berezov, D. Jorissen, H. Takeda, W. Zhu, Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3, and VEGF through disruption of HER/MET crosstalk. Cancer Res. 75, 159-170 (2015).
39. S. Benavente, S. Huang, E. A. Armstrong, A. Chi, K.-T. Hsu, D. L. Wheeler, P. M. Hararic, Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells. Clin. Cancer Res. 15, 1585-1592 (2009).
40. S. B. Keysar, A. Jimeno, More than markers: Biological significance of cancer stem cell-defining molecules. Mol. Cancer Ther. 9, 2450-2457 (2010).
41. P. K. Koh, C. Faivre-Finn, F. H. Blackhall, D. De Ruysscher, Targeted agents in non-small cell lung cancer (NSCLC): Clinical developments and rationale for the combination with thoracic radiotherapy. Cancer Treat. Rev. 38, 626-640 (2012).
42. J. D. Bradley, R. Paulus, R. Komaki, G. Masters, G. Blumenschein, S. Schild, J. Bogart, C. Hu, K. Forster, A. Magliocco, V. Kavadi, Y. I. Garces, S. Narayan, P. Iyengar, C. Robinson, R. B. Wynn, C. Koprowski, J. Meng, J. Beitler, R. Gaur, W. Curran Jr., H. Choy, Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): A randomised, two-by-two factorial phase 3 study. Lancet Oncol. 16, 187-199 (2015).
43. R. S. Herbst, D. Prager, R. Hermann, L. Fehrenbacher, B. E. Johnson, A. Sandler, M. G. Kris, H. T. Tran, P. Klein, X. Li, D. Ramies, D. H. Johnson, V. A. Miller, TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 23, 5892-5899 (2005).
44. N. Ready, P. A. Jänne, J. Bogart, T. Dipetrillo, J. Garst, S. Graziano, L. Gu, X. Wang, M. R. Green, E. E. Vokes; Cancer, Leukemia Group B, Chicago, IL, Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: Cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial. J. Thorac. Oncol. 5, 1382-1390 (2010).
45. C.-P. Huang, M.-F. Tsai, T.-H. Chang, W.-C. Tang, S.-Y. Chen, H.-H. Lai, T.-Y. Lin, J. C.-H. Yang, P.-C. Yang, J.-Y. Shih, S.-B. Lin, ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors. Cancer Lett. 328, 144-151 (2013).
46. S.-M. Che, X.-Z. Zhang, X.-L. Liu, X. Chen, L. Hou, The radiosensitization effect of NS398 on esophageal cancer stem cell-like radioresistant cells. Dis. Esophagus 24, 265-273 (2011).
47. C. Zhou, Y.-L. Wu, G. Chen, J. Feng, X.-Q. Liu, C. Wang, S. Zhang, J. Wang, S. Zhou, S. Ren, S. Lu, L. Zhang, C. Hu, C. Hu, Y. Luo, L. Chen, M. Ye, J. Huang, X. Zhi, Y. Zhang, Q. Xiu, J. Ma, L. Zhang, C. You, Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 12, 735-742 (2011).
48. C. L. Arteaga, J. A. Engelman, ERBB receptors: From oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 25, 282-303 (2014).
49. N. Takebe, D. Nguyen, S. X. Yang, Targeting notch signaling pathway in cancer: Clinical development advances and challenges. Pharmacol. Ther. 141, 140-149 (2014).
50. S. Hu, H. Dai, T. Li, Y. Tang, W. Fu, Q. Yuan, F. Wang, G. Lv, Y. Lv, X. Fan, S. Zhang, R. Jin, Y. Shen, F. Lin, X. Ye, M. Ding, Y. Yang, C. Lei, Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer. Cancer Lett. 382, 32-43 (2016).
51. G. Schaefer, L. Haber, L. M. Crocker, S. Shia, L. Shao, D. Dowbenko, K. Totpal, A. Wong, C. V. Lee, S. Stawicki, R. Clark, C. Fields, G. D. Lewis Phillips, R. A. Prell, D. M. Danilenko, Y. Franke, J.-P. Stephan, J. Hwang, Y. Wu, J. Bostrom, M. X. Sliwkowski, G. Fuh, C. Eigenbrot, A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 20, 472-486 (2011).
52. T method. Nat. Protoc. 3, 1101-1108 (2008).
53. P. Dalerba, S. J. Dylla, I.-K. Park, R. Liu, X. Wang, R. W. Cho, T. Hoey, A. Gurney, E. H. Huang, D. M. Simeone, A. A. Shelton, G. Parmiani, C. Castelli, M. F. Clarke, Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl. Acad. Sci. U.S.A. 104, 10158-10163 (2007).
54. M. H. Ullman-Culleré, C. J. Foltz, Body condition scoring: A rapid and accurate method for assessing health status in mice. Comp. Med. 49, 319-323 (1999).